Most cancer-related deaths are a result of metastasis, and thus the importance of this
process as a target of therapy cannot be understated. By asking 'how can we effectively treat …

Bladder cancer is the sixth most prevalent malignancy in the United States and causes more
than 16,000 deaths annually. The most common clinical presentation is asymptomatic …

Background Patients with advanced urothelial carcinoma have poor overall survival after
platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or …

Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with
localized urothelial carcinoma,, with one study reporting data in cisplatin-ineligible patients …

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival …

Background Few options exist for patients with locally advanced or metastatic urothelial
carcinoma after progression with platinum-based chemotherapy. We aimed to assess the …

Background Novel second-line treatments are needed for patients with advanced urothelial
cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall …

Background Despite standard curative-intent treatment with neoadjuvant cisplatin-based
chemotherapy, followed by radical surgery in eligible patients, muscle-invasive urothelial …

Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-
FGFR inhibitor. Patients and Methods: Patients age≥ 18 years with advanced solid tumors …

Second near-infrared (NIR-II, 1000–1700 nm) fluorescence bioimaging has attracted
tremendous scientific interest and already been used in many biomedical studies. However …